184 related articles for article (PubMed ID: 15304625)
1. Management of hypertriglyceridemia in patients receiving interferon for malignant melanoma.
Wong SF; Jakowatz JG; Taheri R
Ann Pharmacother; 2004 Oct; 38(10):1655-9. PubMed ID: 15304625
[TBL] [Abstract][Full Text] [Related]
2. Potential drug-drug interaction between interferon alfa-2b and gemfibrozil in a patient with malignant melanoma.
Wong SF; Jakowatz JG; Taheri R
Clin Ther; 2005 Dec; 27(12):1942-8. PubMed ID: 16507380
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant interferon in high-risk melanoma: the AIM HIGH Study--United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma.
Hancock BW; Wheatley K; Harris S; Ives N; Harrison G; Horsman JM; Middleton MR; Thatcher N; Lorigan PC; Marsden JR; Burrows L; Gore M
J Clin Oncol; 2004 Jan; 22(1):53-61. PubMed ID: 14665609
[TBL] [Abstract][Full Text] [Related]
4. Depressive mood changes and psychiatric symptoms during 12-month low-dose interferon-alpha treatment in patients with malignant melanoma: results from the multicenter DeCOG trial.
Heinze S; Egberts F; Rötzer S; Volkenandt M; Tilgen W; Linse R; Boettjer J; Vogt T; Spieth K; Eigentler T; Brockmeyer NH; Hinzpeter A; Hauschild A; Schaefer M
J Immunother; 2010 Jan; 33(1):106-14. PubMed ID: 19952950
[TBL] [Abstract][Full Text] [Related]
5. Prospective, randomized, multicenter, double-blind placebo-controlled trial comparing adjuvant interferon alfa and isotretinoin with interferon alfa alone in stage IIA and IIB melanoma: European Cooperative Adjuvant Melanoma Treatment Study Group.
Richtig E; Soyer HP; Posch M; Mossbacher U; Bauer P; Teban L; Svolba G; Wolf IH; Fritsch P; Zelger B; Volc-Platzer B; Gebhart W; Mischer P; Steiner A; Pachinger W; Hintner H; Gschnait F; Rappersberger K; Pilarski P; Pehamberger H;
J Clin Oncol; 2005 Dec; 23(34):8655-63. PubMed ID: 16260701
[TBL] [Abstract][Full Text] [Related]
6. [Sarcoidosis, myasthenia gravis and anterior ischaemic optic neuropathy: severe side effects of adjuvant interferon-alpha-therapy in malignant melanoma?].
Kreutzer K; Bonnekoh B; Franke I; Ulrich J; Gollnick H
J Dtsch Dermatol Ges; 2004 Aug; 2(8):689-94. PubMed ID: 16279234
[TBL] [Abstract][Full Text] [Related]
7. A prospective study of cutaneous adverse events induced by low-dose alpha-interferon treatment for malignant melanoma.
Guillot B; Blazquez L; Bessis D; Dereure O; Guilhou JJ
Dermatology; 2004; 208(1):49-54. PubMed ID: 14730237
[TBL] [Abstract][Full Text] [Related]
8. [Seizures during interferon alpha therapy: three cases in dermatology].
Legroux-Crespel E; Lafaye S; Mahé E; Picard-Dahan C; Crickx B; Sassolas B; Descamps V
Ann Dermatol Venereol; 2003 Feb; 130(2 Pt 1):202-4. PubMed ID: 12671585
[TBL] [Abstract][Full Text] [Related]
9. Baseline mood and psychosocial characteristics of patients developing depressive symptoms during interleukin-2 and/or interferon-alpha cancer therapy.
Capuron L; Ravaud A; Miller AH; Dantzer R
Brain Behav Immun; 2004 May; 18(3):205-13. PubMed ID: 15050647
[TBL] [Abstract][Full Text] [Related]
10. [Hypertriglyceridemia induced by interferon].
Iborra C; Martinet C; Prigent F
Ann Dermatol Venereol; 1996; 123(10):677. PubMed ID: 9615133
[No Abstract] [Full Text] [Related]
11. Correlation between sICAM-1 and depressive symptoms during adjuvant treatment of melanoma with interferon-alpha.
Schaefer M; Horn M; Schmidt F; Schmid-Wendtner MH; Volkenandt M; Ackenheil M; Mueller N; Schwarz MJ
Brain Behav Immun; 2004 Nov; 18(6):555-62. PubMed ID: 15331126
[TBL] [Abstract][Full Text] [Related]
12. Autoimmune antibodies and recurrence-free interval in melanoma patients treated with adjuvant interferon.
Bouwhuis MG; Suciu S; Collette S; Aamdal S; Kruit WH; Bastholt L; Stierner U; Salès F; Patel P; Punt CJ; Hernberg M; Spatz A; ten Hagen TL; Hansson J; Eggermont AM;
J Natl Cancer Inst; 2009 Jun; 101(12):869-77. PubMed ID: 19509353
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant therapy for malignant melanoma.
Stoutenburg JP; Schrope B; Kaufman HL
Expert Rev Anticancer Ther; 2004 Oct; 4(5):823-35. PubMed ID: 15485316
[TBL] [Abstract][Full Text] [Related]
14. The use of interferon alfa as adjuvant therapy for advanced cutaneous melanoma: the need for more evidence.
Kimyai-Asadi A; Usman A
J Am Acad Dermatol; 2000 Oct; 43(4):708-11. PubMed ID: 11004636
[TBL] [Abstract][Full Text] [Related]
15. [Severe hypertriglyceridemia during the course of treatment with interferon-alpha in a patient with chronic hepatitis C].
Bory E; García Rico A; Pedro-Botet J; Sola R
Gastroenterol Hepatol; 1996 Dec; 19(10):542. PubMed ID: 9044758
[No Abstract] [Full Text] [Related]
16. Dose-dependent development of depressive symptoms during adjuvant interferon-{alpha} treatment of patients with malignant melanoma.
Friebe A; Horn M; Schmidt F; Janssen G; Schmid-Wendtner MH; Volkenandt M; Hauschild A; Goldsmith CH; Schaefer M
Psychosomatics; 2010; 51(6):466-73. PubMed ID: 21051677
[TBL] [Abstract][Full Text] [Related]
17. Present status and future prospects for adjuvant therapy of melanoma: time to build upon the foundation of high-dose interferon alfa-2b.
Moschos SJ; Kirkwood JM; Konstantinopoulos PA
J Clin Oncol; 2004 Jan; 22(1):11-4. PubMed ID: 14665613
[No Abstract] [Full Text] [Related]
18. Efficacy and safety profile of fenofibrate-coated microgranules 130 mg, with and without food, in patients with hypertriglyceridemia and the metabolic syndrome: an 8-week, randomized, double-blind, placebo-controlled study.
Davidson MH; Bays H; Rhyne J; Stein E; Rotenberg K; Doyle R
Clin Ther; 2005 Jun; 27(6):715-27. PubMed ID: 16117978
[TBL] [Abstract][Full Text] [Related]
19. Interferon alpha as adjuvant postsurgical treatment of melanoma: a meta-analysis.
Pirard D; Heenen M; Melot C; Vereecken P
Dermatology; 2004; 208(1):43-8. PubMed ID: 14730236
[TBL] [Abstract][Full Text] [Related]
20. Hypertriglyceridaemia following adjuvant interferon-alpha treatment in two patients with malignant melanoma.
Junghans V; Rünger TM
Br J Dermatol; 1999 Jan; 140(1):183-4. PubMed ID: 10215802
[No Abstract] [Full Text] [Related]
[Next] [New Search]
